Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Hormones and Bone Tissue

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Target Cell Response to Hormones

Target Cell Response to Hormones

Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A Complete Hydatidiform Mole Complicated by Theca Lutein Cysts in a Teenager: A Rare Case.

Cureus·2024

Same author

First-Trimester Pregnancy Loss Due to Condyloma Acuminata: A Twisted Tale of Gravidity.

Cureus·2024

Same author

Empowering Women's Health: Insights Into HPV Vaccination and the Prevention of Invasive Cervical Cancer.

Cureus·2023

Same author

Pseudo Broad Ligament Fibroid Posing a Clinical Dilemma: A Case Report.

Cureus·2023

Same author

Maternal Mental Health During Pregnancy: A Critical Review.

Cureus·2022

Search research articles

Related Experiment Video

Updated: May 31, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Non-conventional hormone therapy - Tissue-specific Tibolone-Caution.

Jyotsna Potdar¹

¹Diploma Gynecologic Endoscopic Surgery Keil, Germany.

Journal of Mid-Life Health

|July 1, 2011

Summary

Long-term Tibolone therapy may increase breast cancer risk, challenging its perceived protective effect. This study suggests limiting use to under four years with regular mammography screening for menopausal symptom management.

Keywords:

Breast cancer (Ca)Tibolone menopause

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Related Experiment Videos

Last Updated: May 31, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

Area of Science:

Endocrinology
Oncology
Women's Health

Background:

Tibolone is a synthetic steroid used for menopausal symptom management.
Concerns exist regarding its long-term safety profile, particularly its effect on breast tissue.

Purpose of the Study:

To evaluate the safety of long-term Tibolone therapy.
To investigate the potential association between Tibolone use and breast carcinoma.

Main Methods:

Retrospective study of 50 patients receiving Tibolone therapy.
Analysis of indications, age, duration of therapy, and observed side effects.

Main Results:

Two patients developed breast lumps; one malignant, one benign.
Prolonged Tibolone therapy may be linked to increased breast cancer risk, contrary to prior assumptions.
Recent studies (Million Women Study, LIBERATE) also indicate an elevated risk.

Conclusions:

Tibolone therapy for menopausal symptoms should not exceed four years.
Regular mammography screening is essential for patients on Tibolone therapy.